Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis

Atrial Fibrillation

Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study

Am Heart J

de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano R

doi: 10.1016/j.ahj.2021.01.013

Atrial FibrillationHypertensionThrombosis and Stroke

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension.

Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP

doi: 10.1161/HYPERTENSIONAHA.119.13138.

Atrial Fibrillation

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Eur Heart J.

Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP

doi: 10.1093/eurheartj/ehy861.

Atrial FibrillationHeart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and Stroke

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48

Eur Heart J Acute Cardiovasc Care.

Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, Mercuri MF, Lanz H, Antman EM, Braunwald E, Giugliano RP

doi: 10.1177/

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Circ Arrhythm Electrophysiol.

Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E

doi: 10.1161/CIRCEP.116.004267.

Atrial Fibrillation

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Circulation.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA

doi: 10.1161/CIRCULATIONAHA.

Atrial Fibrillation

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Clin Res Cardiol.

Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH

doi: 10.1007/s00392-019-01594-9.

Thrombosis and Stroke

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Circulation

Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA

doi: 10.1161/CIRCULATIONAHA.120.052216

Atrial Fibrillation

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies

J Am Heart Assoc.

Brouwer TF, Whang W, Kuroki K, Halperin JL, Reddy VY

doi: 10.1161/JAHA.119.013525.

Related content

Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies